Pitt team redesigns an epilepsy drug

A Pitt team has redesigned the structural components of an existing epilepsy drug--retigabine--in order to make it a more potent, targeted therapy. The older drug activated all 5 types of potassium transport channels in the KCNQ category, but only two were necessary for stabilizing the membranes of brain cells. And the same approach could also work against tinnitus. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.